New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
12:27 EDTAEGRAegerion CEO not participating at today's conference, Bloomberg reports
Aegerion CEO Marc Beer will not appear at today's Bank of America Merrill Lynch conference in order to speak meet some "key officials" in Brazil, Bloomberg reports, citing an email from the company. In a March 3 regulatory filing, Aegerion stated, "We are aware that governmental authorities in São Paulo, Brazil are conducting an investigation to determine whether two of our employees have violated anti-corruption laws in connection with prescriptions of lomitapide written in Brazil. We do not believe that a violation of any Brazilian anti-corruption laws has occurred, and intend to vigorously defend ourselves in the event Brazilian authorities ultimately decide to bring action against us or our employees. If our operations in Brazil, or in any other country outside the U.S. in which we sell lomitapide are found, as part of this or any other investigation, to have violated anti-corruption laws or any other laws or regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, charges and fines." Aegerion will be represented at the conference by its CFO.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
09:28 EDTAEGRAegerion board backs CEO amid drug claims, TheStreet reports
Subscribe for More Information
October 27, 2014
10:52 EDTAEGRSeattle Genetics, Aegerion CEOs accused of drug use in lawsuit, TheStreet says
Subscribe for More Information
October 22, 2014
07:35 EDTAEGRCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 20, 2014
07:24 EDTAEGRAegerion price target lowered to $46 from $66 at Leerink
Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use